BioRestorative Therapies (BRTX) Short term Debt (2015 - 2021)

BioRestorative Therapies' (BRTX) quarterly Short term Debt came in at $58970.0 in Q4 2021, up 33.5% on a QoQ basis from $44172.0 in Q3 2021.

BioRestorative Therapies (BRTX) Short term Debt (2015 - 2021) Analysis & Trends

BioRestorative Therapies (BRTX) has 3 years of Short term Debt data on file, last reported at $58970.0 in Q4 2021.

Quarterly Short term Debt changed N/A year-over-year to $58970.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $58970.0 (changed N/A YoY) and the FY2021 annual result came in at $58970.0, changed N/A from the prior year.
Short term Debt advanced to $58970.0 in Q4 2021, from $44172.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $58970.0 in Q4 2021 to a low of $14687.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	BioRestorative Therapies	1.94 Mn	-1.02 Mn	17,964.00

Download Data